![](https://www.medicinesforeurope.com/wp-content/uploads/2016/03/twitter.png)
![](https://www.medicinesforeurope.com/wp-content/uploads/2016/03/Logo_LinkedIn_round.png)
![](https://www.medicinesforeurope.com/wp-content/uploads/2016/03/youtube.png)
![](https://www.medicinesforeurope.com/wp-content/uploads/2016/03/flickr.png)
For the last decade, off-patent medicines, which represent the 70% of dispensed medicines in the European Union, have been subject to strict price regulation, budget austerity measures, and lowest-price tender rules, causing substantial price erosion and an unsustainable situation for manufacturers. This has been exacerbated by the Covid-19 crisis and the war in Ukraine, which has dramatically increased general inflation (now over 9%), raw material costs (risen by between 50-160%), transportation costs (up to 500%) and energy prices.
Read the full Open Letter to EU energy Ministers